1
EXHIBIT 10.27B
[PFIZER LETTERHEAD]
▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇., PH.D.
October 22, 1998 President
Mr. ▇▇▇▇▇ ▇▇▇▇▇
President
▇▇▇▇▇▇▇, Inc.
▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Dear ▇▇. ▇▇▇▇▇,
Further to our recent discussions, Pfizer Inc ("Pfizer") and Abgenix, Inc.
("Abgenix") agree to amend the Collaborative Research Agreement of December 22,
1997 ("1997 Agreement"), to exercise Pfizer's first option to generate
XenoMouseTM antibodies against a second Target Antigen, [*], pursuant to
Section 9.6 of the 1997 Agreement. A Research Plan will be adopted by the
parties in accordance with Section 9.6. Pfizer will fund the [*] Research
Program under the terms set forth in Section 3 of the 1997 Agreement and in the
Letter Amendment to the 1997 Agreement dated May 26, 1998, as appropriate,
according to their terms.
All other terms and conditions of the 1997 Agreement shall remain unchanged and
in full force and effect. Please sign both copies of this Letter Amendment to
the 1997 Agreement and return one original to [*] at the above address.
Sincerely,
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
▇▇▇▇▇▇ ▇. ▇▇▇▇▇, ▇▇.
Agreed:
ABGENIX INC.
By: /s/ ▇. ▇▇▇▇▇ ▇▇▇▇▇
------------------------
Title: President & CEO
---------------------
Date: 10/23/98
----------------------
------------------
* Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to
the omitted portions.
